IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Main Line Health
• Treatments: Chloroquine; Chloroquine diphosphate

Criteria

Inclusion Criteria:

• Patients with histologically confirmed primary solid malignancy

• Patients with single or multiple brain metastases

• Patients with metastasis diameter < 5 cm

• Age > 18

• Clearance from the patient's physician that treatment with chloroquine should not pose a problem to the patient

Exclusion Criteria:

• Patients with a history of hypotension, cardiomyopathy, epilepsy, seizures

• Patients with impaired renal function

• Patients with psoriasis, porphyria

• Patients with known hypersensitivity to 4-aminoquinoline compounds

• Pregnancy, nursing

• Prior radiotherapy

• During the chloroquine treatment, patients complaining from visual or auditory disturbances, and patients suffering from acute gastrointestinal problems i.e. Anorexia, nausea, vomiting, diarrhea, abdominal cramps